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Abstract Epigenetic alterations, including methylation,
have been shown to be an important mechanism of gene
silencing in cancer. Ependymoma has been well charac-
terized at the DNA copy number and mRNA expression
levels. However little is known about DNA methylation
changes. To gain a more global view of the methylation
proﬁle of ependymoma we conducted an array-based
analysis. Our data demonstrated tumors to segregate
according to their location in the CNS, which was associ-
ated with a difference in the global level of methylation.
Supratentorial and spinal tumors displayed signiﬁcantly
more hypermethylated genes than posterior fossa tumors,
similar to the ‘CpG island methylator phenotype’ (CIMP)
identiﬁed in glioma and colon carcinoma. This hyperme-
thylated proﬁle was associated with an increase in
expression of genes encoding for proteins involved in
methylating DNA, suggesting an underlying mechanism.
An integrated analysis of methylation and mRNA expres-
sion array data allowed us to identify methylation-induced
expression changes. Most notably genes involved in the
control of cell growth and death and the immune system
were identiﬁed, including members of the JNK pathway
and PPARG. In conclusion, we have generated a global
view of the methylation proﬁle of ependymoma. The data
suggests epigenetic silencing of tumor suppressor genes is
an important mechanism in the pathogenesis of supraten-
torial and spinal, but not posterior fossa ependymomas.
Hypermethylation correlated with a decrease in expression
of a number of tumor suppressor genes and pathways that
could be playing an important role in tumor pathogenesis.
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Introduction
Ependymoma is the third most common pediatric tumor of
the central nervous system (CNS), accounting for 6–12%
of brain tumors in children. Prognosis for patients with
ependymoma is relatively poor with a 5 year overall sur-
vival rate of 24–75% [68, 75]. Currently tumors are treated
by surgical resection followed by radiotherapy, with the
extent of resection one of the most consistent prognostic
markers. Ependymomas are found intracranially and in the
spinal cord. 90% of pediatric cases occur intracranially
with 70% arising in the posterior fossa.
Molecular proﬁling has revealed genetic and transcrip-
tional differences between tumors arising in different
locations. Copy number analysis using CGH and array
CGH [48, 62], and more recently, high resolution SNP
arrays [28], has demonstrated location speciﬁc differences.
Analysis of global transcriptional proﬁling data has also
revealed distinct location based signatures, based on both
mRNA and miRNA expression [28, 48, 52, 62]. Studies
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DOI 10.1007/s00401-011-0904-1suggest ependymomas from different locations arise from
distinct populations of neural stem cells which may help
explain the observed location based biological differences
[28, 62]. Despite the large amount of molecular data gen-
erated, very few candidate genes and pathways have been
identiﬁed in ependymoma that could be used in a more
targeted approach to therapy [40].
Epigenetic changes, such as methylation, are frequently
seen in a variety of tumors and provide an alternative
mechanism from deletion or mutation for silencing of
tumor suppressor genes. DNA methylation is mediated by
DNA methyltransferase enzymes (DNMT1, DNMT3A,
DNMT3B) which transfer a methyl group to cytosines
found within CpG dinucleotides [5, 23]. This allows a
complex containing methyl-CpG binding domain proteins
to bind to the methylated DNA. The complex interacts with
histone deacetylases, histone methyltransferases and chro-
matin remodeling enzymes to alter the chromatin into a
state that is transcriptionally repressive [6].
To date only a few studies have analyzed methylation
changes in ependymoma using a candidate gene approach.
Tumor suppressor genes including CDKN2A, CDKN2B,
HIC1,RASSF1A,CASP8,MGMT,andTP73havebeenshown
to be hypermethylated in ependymomas [2, 22, 46, 58, 64].
To gain a more global view of the methylation proﬁle of
ependymoma we utilized the GoldenGate Methylation
Cancer Panel I (Illumina, San Diego, CA, USA). This array
measures the methylation level of up to 1,505 independent
CpG sites, representing 807 genes, which include known
tumor suppressor genes and oncogenes, plus genes
involved in cellular functions such as DNA repair, cell
cycle control, differentiation and apoptosis. Our analysis of
a cohort of 98 ependymomas revealed a difference in the
global level of methylation between tumors arising in dif-
ferent locations. Tumors from a supratentorial or spinal
location displayed a hypermethylated proﬁle which was
associated with an increased expression of genes encoding
for proteins that form part of the DNA methylation
machinery, suggesting an underlying mechanism. An
integrated analysis of methylation and mRNA expression
data allowed us to identify methylation-induced expression
changes. Most notably genes involved in the regulation of
apoptosis and cell growth were affected, including mem-
bers of the JNK pathway, PPARG and RASSF1A, in
addition to genes involved in the immune system.
Materials and methods
Sample cohort
Samples were collected from Children’s Cancer and Leu-
kaemia Group (CCLG) and the Cooperative Human Tissue
Network (CHTN). Ninety-eight snap-frozen ependymoma
samples were used in the methylation proﬁling, including
73 primary and 25 recurrent tumors. Primary and sub-
sequent recurrent tumor samples were used from nine
patients. The cohort also contained 12 recurrent tumors
from nine patients with no paired primary sample. The
mean and median age of the cohort was 6.8 and 6 years,
respectively. Of the primary tumors 53% were posterior
fossa, 23% supratentorial and 15% spinal. Data were
unavailable for six tumors. After central histopathological
review of 72/73 primary tumors, 7% were grade I, 52%
grade II and 40% grade III. One tumor was acquired after
central review. Local review classed the tumor as grade II/
III. Of the grade I tumors, all were myxopapillary spinal
ependymomas.
Clinical information was obtained from the CCLG,
CHTN and local centers. Multiple Centre Research Ethics
Committee (MREC) approval was obtained for the study.
Consent for use of tumor samples was taken in accordance
with national tumor banking procedures and the Human
Tissue Act. Work was conducted in premises licensed
under the Human Tissue Act.
DNA extraction
Prior to DNA extraction, a small piece of tissue was pre-
pared on a slide as a diagnostic smear with subsequent
hematoxylin and eosin staining. The slides were reviewed
by a pathologist to determine if tumor cells were present.
DNA was extracted from 10 mg of tissue. DNA was also
extracted from the neural stem cell line ReNcell VM
(Millipore), using 1 million cells per extraction. Each
sample was lysed in lysis buffer (50 mM Tris pH 8,
100 mM EDTA pH 8, 100 mM NaCl, 1% SDS) and pro-
teinase K (20 mg/ml) at 37C overnight. DNA was
obtained by phenol:chloroform extraction followed by
isopropanol precipitation. DNA quality was checked by
electrophoresis of 1 ll of sample through a 1% agarose gel
at 120 V.
Methylation array analysis
DNA from 98 ependymoma samples plus three replicates
of the ReNcell VM cell line was processed using the
GoldenGate
 Cancer Panel I assay for methylation (Illu-
mina) at the Wellcome Trust Centre for Genetics, Oxford,
UK, according to manufacturer’s instructions. In brief,
500 ng genomic DNA from each sample underwent
bisulphite conversion. Half of the sample was then used in
the GoldenGate
 assay. Following hybridization and
washing, slides were scanned using the Illumina Beadar-
ray
TM Reader. Initial data quality control measures were
undertaken using Beadstudio v.32 methylation module
TM
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123(Illumina). Probes with aberrant signal intensity were
identiﬁed using a calculated probe detection value. Sam-
ples were excluded from further analysis if more than 1%
of the 1,505 probes had a detection p value greater than
0.05. Spatial artifacts were identiﬁed using the Beadarray
Subversion of Harshlight (BASH) [8] feature within the
beadarray package (http://www.bioconductor.org). Sam-
ples with signiﬁcantly large spatial defects, greater than
25% of the array area, were excluded from further analysis.
Data analysis was undertaken in R and Bioconductor
.
After background signal correction, a beta value was
attributed to each measured probe, representing the level of
methylation, with values ranging from zero (unmethylated)
to one (hypermethylated). Before downstream analysis,
probes from the X chromosome were removed. Boot-
strapped unsupervised hierarchical clustering was
performed using the R package ‘pvclust’ [61], using
Euclidean distance, average agglomeration and 10,000
replications. The observed cluster patterns were veriﬁed
using principal component analysis using the ‘rgl’, ‘pvc-
lust’ and ‘cluster’ packages.
Statistical comparisons were performed in Gene-
SpringGX 11.0 (Agilent, Santa Clara, Ca, USA). Genes
showing signiﬁcantly different methylation levels between
groups were identiﬁed using a Kruskal–Wallis test with a
Benjamini and Hochberg multiple test correction [4].
Genes were considered signiﬁcant if their p value was less
than 0.05. Additional genes were removed if the difference
in average beta values between groups was less than 0.34.
Identiﬁed gene lists were analyzed using the online func-
tional annotation tool DAVID [25, 26] and Ingenuity
Pathway Analysis (IPA) 9.0 (http://www.ingenuity.com).
To determine global levels of hypo- or hypermethylation
the number of probes with beta values less than or equal to
0.2 (hypomethylation), or values greater than or equal to
0.8 (hypermethylation) were calculated. The numbers cal-
culated for each group were compared using a t-test to
identify signiﬁcant differences.
Bisulphite sequencing
Seventeen tumors that had been run on the methylation
arrays were further analyzed by bisulphite sequencing. One
sample was a recurrence, the rest primary tumors. Five
tumors were supratentorial, three spinal, and nine posterior
fossa.
1 lg DNA from each sample was bisulphite converted
using the CpGenome DNA modiﬁcation kit (Millipore,
Billerica, MA, USA). Primers were designed to amplify a
product, from bisulphite modiﬁed DNA, covering the
selected methylation loci (Online Resource 1). PCR reac-
tions were carried out by incubating bisulphite modiﬁed
DNA with 1.25 U of platinum taq (Invitrogen, Carsbad,
CA, USA), 8.3 mM dNTPs, 2 mM MgCl2 and forward and
reverse primers (1 lM). Optimized levels of betaine and
DMSO were added to reactions for speciﬁcity (Online
Resource 1). PCR conditions were; 95C for 5 min fol-
lowed by 40 cycles of 95C for 30 s, an annealing
temperature speciﬁc to each primer pair (Online Resource
1) for 1 min and 72C for 1 min. This was followed by a
ﬁnal extension step at 72C for 10 min.
PCR products were puriﬁed by incubation with 0.3 U
shrimp alkaline phosphatase (Promega, Madison, WI,
USA) and 1.5 U exonuclease I (NEB, Ipswich, MA, USA)
at 37C for 8 min, followed by 15 min at 72C. Sequenc-
ing reactions were undertaken by Source Bioscience
(Nottingham, UK). Sequences were analyzed using Muta-
tion Surveyor v3.97 (SoftGenetics, PA, USA). The level of
methylation was represented by the percentage of cytosine,
calculated using the simpliﬁed allele ratio function.
Expression array analysis
Previously published ependymoma mRNA expression data
were used [28]. Ten samples from this study were run on the
methylation arrays in our study which included eight pri-
mary tumors, and a second and third recurrent sample from
one patient. Five of the samples were supratentorial and ﬁve
located in the posterior fossa. Data analysis was initially
undertaken using GeneSpringGX 11.0 (Agilent). Raw data
(CEL ﬁles) downloaded from Gene Expression Omnibus
(GEO) under the accession number GSE21687 were pro-
cessed using the robust multiarray average (rma) algorithm.
A number of the tumors used in this study were from adult
patients. These were excluded from comparisons to our
methylation data on pediatric ependymomas. Previously
published normal fetal brain regional expression data were
additionally analyzed [41]. MAS5 processed data were
downloaded from GEO (accession number GSE1397).
Genes differentially expressed between groups were
identiﬁed using an ANOVA test with a Benjamini and
Hochberg multiple test correction [4]. Genes were con-
sidered signiﬁcant if their p value was less than 0.05.
Identiﬁed gene lists were analyzed using IPA. A compar-
ison between methylation and expression array data, for
genes showing signiﬁcant differential methylation between
tumor location groups, was analyzed for the 10 samples run
on both array platforms using Pearson’s correlation in
SPSS (IBM, NY, USA).
Quantitative PCR
Total RNA was extracted from 19 ependymoma frozen
tumor samples. Fifteen were primary tumors and four were
recurrences. Twelve were posterior fossa, ﬁve supratento-
rial and two spinal. 40–50 mg of tissue were used for
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123extraction using the mirVana
TM miRNA Isolation kit
(Applied Biosystems, Carlsbad, CA, USA). After extraction
RNA was treated with DNase (Promega) (2 U) at room
temperature for 15 min. cDNA synthesis was carried out by
incubating 500 ng RNA with 200 U reverse transcriptase
(Fermentas, St. Leon-Rot, Germany) at 42C for 1 h.
Reactions were terminated by incubating at 70C for 5 min.
A control was included for each sample where reverse
transcriptase was excluded from the reaction mix to test for
genomic DNA contamination in subsequent PCR reactions.
Primer sequences for quantitative PCR (qPCR) are given
in Online Resource 1. PCR reactions were carried out by
incubating an equivalent of 8.3 ng of starting RNA with 1Q
Custom SYBR Green Supermix (BIO-RAD, Hercules, CA,
USA) and forward and reverse primers (100 nM). The
CFX96 real time PCR machine (BIO-RAD) was used. PCR
conditions were; 95C for 10 min followed by 40 cycles of
95C for 30 s, an annealing temperature speciﬁc to each
primer pair (Online Resource 1) for 1 min and 72C for
1 min. This was followed by a dissociation (melting curve)
analysis. Data were normalized using GAPDH. Each cDNA
sample was analyzed in triplicate. Primer efﬁciency and
precision were calculated using a standard curve. Relative
expression to a calibrator sample (fetal brain or selected
tumor sample) was calculated using the Pfaﬂ equation [54].
Results
Hypermethylated proﬁle identiﬁed based on tumor
location
Methylation array data were generated for 98 ependymoma
samples including 73 primary tumors and 25 recurrences.
The data were initially analyzed by unsupervised hierar-
chical clustering and principal component analysis (Fig. 1).
Tumors mainly grouped according to location, separating
into groups arising in supratentorial, posterior fossa and
spinal regions of the CNS. No other factor displayed an
association with the cluster groups. Survival analysis
revealed no signiﬁcant differences in patient outcome
between cluster groups (data not shown).
Eighty-four probes, representing 70 genes, showing
signiﬁcant differences in methylation levels between
tumors from different locations were identiﬁed using a
Kruskal–Wallis test (Online Resource 2). No signiﬁcant
differences were found when clinical groups, including age
at diagnosis, patient sex and tumor grade, were compared.
Additionally no differences were identiﬁed between pri-
mary and recurrent tumors.
We noted that a high proportion of the genes displaying
location-based methylation differences were hypermethy-
lated in supratentorial and spinal tumors (75%) and
hypomethylated in posterior fossa tumors (25%) (Fig. 2a,
b). To investigate this further we compared the numbers of
probes in each group which were totally unmethylated (beta
value B 0.2) or totally methylated (beta value C 0.8).
Posterior fossa tumors displayed a signiﬁcantly higher
number of probes with no methylation (p value 0.0005) and
a signiﬁcantly lower number of probes with complete
methylation (p value 0.0009). This hypermethylated phe-
notype, seen in supratentorial and spinal ependymomas,
was also reﬂected at the expression level. Using an inde-
pendent mRNA expression array dataset, originally
published by Johnson et al. [28] (Geo accession number
GSE21687), we found more genes, across the whole array,
displayed up-regulated expression in posterior fossa tumors
compared to supratentorial and spinal (Fig. 2c).
Genes encoding for proteins involved in the methylation
of DNA, including the DNA methyltransferases DNMT1,
DNMT3A and DNMT3B, displayed statistically signiﬁcant
differential expression in posterior fossa tumors compared
to supratentorial and spinal tumors (Fig. 3). Most genes in
this pathway displayed up-regulated expression in supra-
tentorial and spinal tumors, suggesting the de-regulated
expression of components of the methylation machinery
may be the mechanism by which the hypermethylated
proﬁle is being generated.
Identiﬁcation of candidate genes
Genes with signiﬁcant differences in methylation levels
between tumors from different locations (Online Resource
2) were analyzed using the online functional annotation
tool DAVID [25, 26]. Genes identiﬁed included those
involved in the regulation of apoptosis and cell growth.
The growth regulator PPARG was methylated in supra-
tentorial and spinal tumors. Genes involved in apoptosis
included TP73, which was methylated in supratentorial
tumors, and HDAC1, which was methylated in spinal
tumors. The tumor suppressor gene RASSF1A displayed
hypermethylation in all intracranial tumors. Members of
the MAPKKK cascade and the JAK/STAT pathway were
also signiﬁcantly enriched. This included members of the
c-Jun N-terminal kinase (JNK) signaling pathway;
MAPK10 and MAP3K1 which displayed hypermethylation
in supratentorial and spinal tumors. A relatively low
number of genes displayed hypermethylation in posterior
fossa tumors. Genes in this group included IRF7, FABP3
and CRIP1.
Further analysis using IPA identiﬁed signiﬁcant
enrichment for signaling pathways including DNA meth-
ylation and transcriptional repression signaling, JNK
signaling, PPAR signaling, death receptor signaling, JAK/
STAT signaling and TGFB signaling (Online Resource 3).
Many pathways involving the innate and adaptive immune
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123system, particularly cytokine signaling, also displayed
signiﬁcant enrichment.
Analysis at the gene expression level revealed
correlations with the methylation data
To identify which methylation alterations induced mRNA
expression level changes we again analyzed ependymoma
expression array data originally published by Johnson et al.
[28]. Methylation and expression array data were directly
compared for 10 tumor samples which were run on both
array platforms. A Pearson’s correlation was calculated for
the genes which displayed signiﬁcant differential
methylation between tumors from different locations.
Seventeen out of 84 (20%) probes, representing 16 genes,
displayed a signiﬁcant inverse correlation (Table 1).
We additionally identiﬁed genes showing differential
expression between tumors arising in supratentorial, pos-
terior fossa or spinal locations across the whole cohort
analyzed on the mRNA expression arrays (Online
Resource 4). Out of the genes identiﬁed in the methylation
analysis, 40% also displayed a signiﬁcant difference in
mRNA expression. The expression levels for approxi-
mately half of these genes displayed an inverse pattern to
that found in the methylation data, suggesting methylation
was directly inﬂuencing mRNA expression (Table 2).
Fig. 1 a Hierarchical clustering dendogram of ependymomas using
all methylation probes. Clustering was carried out using the ‘pvclust’
package in R. AU p values are displayed in red. Tumors grouped
according to location in the CNS. Other clinical factors including
WHO grade, age at diagnosis, whether a sample was a primary or
recurrent tumor and whether patients with a primary tumor had a
subsequent event (recurrence or death) are displayed. No other factor
displayed an association with the cluster groups. b The segregation of
tumors arising in different locations was conﬁrmed using principal
component analysis
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123Eight out of the 16 genes which displayed an inverse
correlation between methylation and expression levels for
the 10 ependymomas analyzed on both array platforms
also displayed signiﬁcant differential mRNA expression
across the whole cohort.
Genes identiﬁed included those involved in the control
of cell growth and death such as MAPK10 and PPARG. A
number of genes involved in the immune response were
also found including NOD2, IRF7, IRAK3, OSM and PI3.
As only a small number of spinal tumors were included in
the mRNA expression analysis it was difﬁcult to identify
which genes correlated with the methylation data in this
group.
We analyzed the location based mRNA gene lists iden-
tiﬁed in the statistical analysis using IPA. One-third of
canonical pathways identiﬁed in the methylation analysis
were also enriched for at the mRNA expression level
(Online Resource 5). Many of the pathways that overlapped
were involved in cell death and the immune response.
Analysis demonstrated that a number of genes from the JNK
signaling pathway displayed differential expression
between tumors arising in different CNS locations (Fig. 4).
Fig. 2 Hierarchical clustering of probes displaying signiﬁcant dif-
ferences in methylation between tumors from different locations (a).
On the heat map red boxes represent high beta values and green low
beta values. Posterior fossa (PF) tumors formed a separate cluster to
the rest of the tumors and displayed fewer hypermethylated (red)
probes compared to supratentorial (ST) and spinal (SP) tumors. The
difference in the level of hypermethylation is also illustrated in a
volcano plot (b). The negative logged p value (Kruskal–Wallis test) is
displayed along the y-axis. The difference in average beta values
between the posterior fossa vs the supratentorial and spinal tumors is
displayed along the x-axis. Probes with a signiﬁcant p value (\0.05)
and a difference in beta value greater than 0.34 are highlighted in red.
A greater number of probes were hypomethylated in posterior fossa
tumors (negative DNA methylation difference). The methylation
phenotype seen was reﬂected at the mRNA expression level
illustrated by a volcano plot (c). A global comparison using all
probes on the array was undertaken comparing posterior fossa to
supratentorial and spinal tumors. The negative log p value (t-test PF
vs. ST ? SP) is displayed along the y-axis and the logged fold change
[PF/(ST ? SP)] along the x-axis. Probes with a signiﬁcant p value
(\0.05) and a fold change greater than two are highlighted in red.A
greater number of probes were up-regulated in posterior fossa
ependymomas (positive fold change) compared to supratentorial
and spinal tumors
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123Validation of selected candidate genes
The methylation status of six genes; MAPK10, PPARG,
FABP3, EYA4, CRIP1 and IRF7 was validated using
bisulphite sequencing. Genes displaying hypermethylation
in each location tumor group, which also displayed an
inverse correlation at the mRNA expression level, were
chosen. The pattern of methylation identiﬁed by bisulphate
sequencing signiﬁcantly correlated with the array data
(Fig. 5). Adjacent CpGs also displayed a signiﬁcant cor-
relation with the validated CpG for the majority of genes
analyzed (data not shown).
The mRNA expression of the same six genes was vali-
dated using qPCR. All genes displayed a similar pattern of
expression to the mRNA expression array data and an
inverse pattern to the methylation array data (Online
Resource 6).
Comparison to normal brain
Previous studies have demonstrated differences in the level
of methylation between regions of the adult brain [20, 34].
This could suggest that the segregation of the ependymo-
mas according to location that we found could have been
affected by ‘‘contaminating’’ surrounding brain tissue. We
checked for the presence of normal tissue using H and E
stained smears of the tumor samples. However, this only
analyzed a small piece of the tissue used. The study by
Ladd-Acosta et al. [34] demonstrated signiﬁcant differ-
ences in methylation between adult cerebral cortex and
cerebellum using the same array platform as we used in our
study. We compared their gene list to genes showing sig-
niﬁcant differences in methylation between supratentorial
and posterior fossa ependymomas (Online Resource 7).
Using the same stringency cut offs, only two genes, LCN2
and WRN2, were found on both lists. Additionally, a
similar percentage of genes were hypermethylated in each
normal brain region (cerebral cortex 60%, cerebellum
40%) compared to the supratentorial bias observed in the
ependymomas (supratentorial 79%, posterior fossa 21%).
We were unable to obtain methylation data for fetal
brain regions. Therefore, we looked at RNA expression,
using a previously published dataset (GEO accession
GSE1397) [41]. In ependymoma, we found that approxi-
mately 20% of genes differentially methylated between
location groups displayed an inverse pattern of mRNA
expression. If the differences in methylation were due to
‘‘contaminating’’ normal tissue we would expect to see a
Fig. 3 Expression differences
in genes involved in DNA
methylation and transcriptional
repression signaling were seen
between ependymomas from
different CNS locations. The
ﬁgure illustrates expression
differences between
supratentorial and posterior
fossa tumors only as very few
spinal tumors were analyzed at
the mRNA expression level.
Genes highlighted in green
represent those with higher
expression in supratentorial
tumors and genes in pink those
with higher expression in
posterior fossa tumors. The
majority of genes displayed
higher expression in
supratentorial tumors. The
image in the ﬁgure was taken
from IPA
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123similar overlap with normal fetal brain. We identiﬁed
genes with signiﬁcantly different RNA expression between
cerebrum and cerebellum samples using a t-test (Online
Resource 8). We found that none of the genes we identiﬁed
to be differentially methylated between supratentorial and
posterior fossa ependymomas (Online Resource 7) showed
signiﬁcantly different mRNA expression between normal
fetal brain regions. These results suggest the differences we
found are tumor speciﬁc and not due to ‘‘contaminating’’
normal tissue.
Previous studies have shown similarities between
ependymoma expression proﬁles and those of neural stem
cells [28, 62]. We therefore compared our methylation
proﬁles to those from the fetal neural stem cell line ReN-
cell VM. Hierarchical clustering and PCA, using the genes
which displayed signiﬁcant methylation differences
between the ependymomas from different locations,
showed the neural stem cells grouped with the supraten-
torial and spinal ependymomas (Fig. 6). Statistical
comparisons between tumors from different locations and
the neural stem cells showed that only the posterior fossa
tumors displayed a relatively large number of signiﬁcant
differences (Online Resource 9). Only one gene, DUSP4,
displayed a signiﬁcant difference in methylation level
between supratentorial ependymomas and neural stem
cells, being more methylated in the stem cells. No
signiﬁcant differences were found between spinal tumors
and neural stem cells.
Discussion
We have analyzed a large cohort of ependymomas to
identify alterations in methylation across the genome.
Through an integrated analysis with ependymoma mRNA
expression array data we have identiﬁed global changes in
methylation patterns and speciﬁc candidate genes and
pathways that may be involved in tumor pathogenesis. Our
analysis suggests epigenetic silencing of tumor suppressor
genes, through DNA methylation, is an important mecha-
nism in the pathogenesis of supratentorial and spinal
ependymomas.
As previously shown with DNA copy number and
mRNA expression data [28, 62], we observed location
based differences at the level of methylation. Our analysis
revealed a global difference in the methylation levels
between tumors arising in different regions of the CNS.
Ependymomas from supratentorial and spinal locations
displayed signiﬁcantly more hypermethylated genes than
tumors from the posterior fossa region, suggesting this may
be an important mechanism of tumor suppressor gene
inactivation in supratentorial and spinal but not posterior
Table 1 Genes displaying a signiﬁcant correlation between methylation and mRNA expression array data for the 10 ependymomas analyzed on
both array platforms
Gene Methylation probe ID Expression probe ID Pearson’s correlation (r) p value
NAT2 NAT2_P11_F 206797_at -0.894 \0.001
NOD2 CARD15_P302_R
a 220066_at -0.922 \0.001
PPARG PPARG_P693_F 208510_s_at -0.938 \0.001
IRF7 IRF7_E236_R 208436_s_at -0.793 0.006
IRF7_P277_R 208436_s_at -0.866 0.001
CHI3L2 CHI3L2_E10_F 213060_s_at -0.783 0.007
MAPK10 MAPK10_E26_F 204813_at -0.778 0.008
OSM OSM_P34_F 230170_at -0.743 0.014
EYA4 EYA4_P794_F 207327_at -0.707 0.022
238877_at -0.737 0.015
TAL1 TAL1_E122_F 1561651_s_at -0.732 0.016
IRAK3 IRAK3_P185_F 213817_at -0.725 0.018
HDAC1 HDAC1_P414_R 201209_at -0.694 0.026
PI3 PI3_P1394_R 203691_at -0.674 0.033
41469_at -0.695 0.026
RBP1 RBP1_P426_R 203423_at -0.687 0.028
CRIP1 CRIP1_P874_R 205081_at -0.686 0.029
BCR BCR_P346_F 202315_s_at -0.682 0.030
217223_s_at -0.639 0.047
TJP2 TJP2_P518_F 202085_at -0.673 0.033
a CARD15 was renamed as NOD2
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123fossa ependymomas. This was reﬂected at the mRNA
expression level. A larger proportion of genes displaying
tumor location differences in expression were up-regulated
in posterior fossa tumors compared to ependymomas from
other CNS locations. Normally most gene promoters are
unmethylated [29]. However, increased methylation of
CpG islands in the promoter regions of a large number of
genes has been seen in a variety of cancers. A ‘CpG island
methylator phenotype’ (CIMP) was originally described in
a subset of colon carcinomas [63, 67]. The same methylator
phenotype has also been described in glioma [35, 49].
In some cancers a hypermethylated phenotype has been
associated with poor outcome [27]. However, in glioma the
‘methylator’ subgroup was linked to a better prognosis
[49]. We did not ﬁnd an association between methylation
and survival.
Without an appropriate normal control it cannot be
concluded whether the hyper- or hypomethylation proﬁles
are closer to normal for ependymoma. A recent study of the
methylation levels of CpG sites within or ﬂanking alu
elements in ependymoma identiﬁed a global loss in meth-
ylation which was associated with more aggressive or
recurrent tumors [69]. In our study, we found no signiﬁcant
differences in methylation between primary and recurrent
tumors. However, in the study by Xie et al. loci exhibiting
a signiﬁcant loss of methylation tended to be further from
transcription factor binding sites suggesting they were
different to the CpG sites included in our analysis, which
were designed to be in the vicinity of gene promoters. In
cancer, hypermethylation within gene promoters is more
common than hypomethylation. The latter is more fre-
quently found in intergenic regions [13, 19, 44, 56]. This
suggests the hypermethylation we found in supratentorial
and spinal tumors is more likely to be the aberrant proﬁle.
The methylation and expression data both suggested the
underlying mechanism behind the global hypermethylation
seen in supratentorial and spinal ependymomas may be due
to deregulation of the DNA methylation machinery. Over
expression of genes involved in the methylation of DNA
has been seen in other cancers and has been associated with
CpG hypermethylation [47]. In contrast, loss of expression
of these genes has also been associated with global hy-
pomethylation [18, 47].
Reducing hypermethylation therapeutically may be a
promising approach in the treatment of some cancers.
Hypomethylation therapies have been approved for use in
liquid tumors [29]. However, these therapies risk activating
methylated oncogenes. Further analysis is needed to
Table 2 Genes displaying signiﬁcant differences in mRNA expression between tumors from different CNS locations that were also identiﬁed in
the methylation analysis
Probe set ID Corrected
p value
Regulation ((PF) vs.
(SP))
Regulation ((PF) vs.
(ST))
Regulation ((SP) vs.
(ST))
Gene symbol
208510_s_at 4.58E-07 Up Up Up PPARG
204379_s_at 1.02E-06 Up Down Down FGFR3
204380_s_at 2.69E-04 Up Down Down FGFR3
204813_at 2.64E-05 Up Up Up MAPK10
206797_at 0.001860389 Down Up Up NAT2
213060_s_at 0.002203304 Up Up Down CHI3L2
239782_at 0.003380862 Up Up Up RBP1
203423_at 0.019743502 Down Up Up RBP1
208436_s_at 0.007062891 Down Down Up IRF7
226602_s_at 0.011980913 Up Up Up BCR///FLJ42953///LOC100133163///
LOC728468
213441_x_at 0.012686884 Up Up Down SPDEF
214403_x_at 0.040593553 Up Up Down SPDEF
213442_x_at 0.048410457 Up Up Down SPDEF
214404_x_at 0.038640525 Up Up Down SPDEF
205738_s_at 0.013991439 Up Down Down FABP3
238877_at 0.037761625 Down Up Up EYA4
208568_at 0.039600316 Up Up Down MC2R
205168_at 0.040356502 Up Down Down DDR2
Only the genes which displayed an inverse pattern to the methylation data are listed. Probes that are italicized represent genes which also
displayed a signiﬁcant inverse correlation between the methylation and expression data for the tumor samples run on both array platforms
(Table 1)
PF posterior fossa, ST supratentorial, SP spinal
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123determine the importance of the hypermethylation seen in
ependymoma to determine how effective hypomethylation
therapies would be.
Our data suggested that, at the DNA methylation level,
supratentorial and spinal ependymomas displayed more
similarities than supratentorial and posterior fossa tumors.
This is somewhat surprising as spinal ependymomas differ
clinically, being much rarer in children and having a better
prognosis than intracranial tumors [38, 45]. Spinal tumors
also display a distinct copy number proﬁle from supra-
tentorial tumors, characteristically showing gains or losses
of large genomic regions compared to supratentorial
tumors which display more focal alterations [28]. Spinal
tumors also display signiﬁcant differences in mRNA
expression compared to intracranial tumors [62].
Tumors could also segregate according to location if
‘‘contaminating’’ surrounding brain tissue was biasing the
results. Our meta-analysis of normal adult brain methyla-
tion and fetal brain expression data suggests this is not the
case. The genes displaying differences between samples
from supratentorial and posterior fossa locations were not
the same as the differences seen in the tumor samples
suggesting the methylation patterns are tumor speciﬁc.
Studies have suggested ependymomas found in different
locations within the CNS arise from distinct progenitor cell
populations [28]. The RNA expression patterns of supra-
tentorial ependymomas was shown to resemble mouse
neural stem cells isolated during embryonic development
and spinal tumors that of adult mouse neural stem cells,
suggesting the tumors had retained or recapitulated the
expression proﬁle of these stem cells. Our analysis dem-
onstrated that human fetal neural stem cells displayed a
similar methylation pattern to supratentorial tumors sup-
porting this hypothesis. All the spinal tumors we analyzed
were pediatric which may explain why we found them to
be similar to fetal neural stem cells in contrast to Johnson
et al. who found spinal tumors to be more similar to adult
cells. The published study by Johnson et al. mainly
Fig. 4 Signiﬁcant differences in mRNA expression were seen for
genes involved in the JNK signaling pathway between tumors arising
in different CNS locations. The ﬁgure illustrates expression differ-
ences between supratentorial and posterior fossa tumors only as very
few spinal tumors were analyzed at the mRNA expression level.
Genes highlighted in green represent those with higher expression in
supratentorial tumors and genes in pink those with higher expression
in posterior fossa tumors. The majority of genes displayed higher
expression in supratentorial tumors. However, MAPK10 (JNK3) and
the downstream target c-Jun displayed higher expression in posterior
fossa tumors. The image in the ﬁgure was taken from IPA
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123comprised adult spinal ependymomas. The neural stem
cells we analyzed were derived from the ventral mesen-
cephalon of fetal brain tissue. It may be that posterior fossa
tumors arise from stem or progenitor cells from a different
location.
It has been reported that cell lines display increased
methylation compared to uncultured cells [60]. The neural
stem cell line we used was also immortalized using v-myc
which could potentially alter the methylation proﬁle from
that of the original cells. However, it has been demon-
strated that the immortalized cells behave like the original
stem cells and retain a normal karyotype even after many
passages [15]. Additionally, the similarity we found
between the methylation proﬁles of the neural stem cells
and spinal and supratentorial ependymomas is unlikely to
have occurred by chance.
Integration of methylation and mRNA expression data
allowed us to identify methylation-induced gene expres-
sion changes. Most notably, we identiﬁed many genes
involved in the control of cell growth and death and
pathways involved in the immune system. Only 20% of
genes displayed an inverse correlation between methyla-
tion and expression data. This is consistent with previous
cancer studies [24, 49, 55]. Methylation can only control
the potential for gene expression. Therefore, if the signal to
induce expression is not present no gene expression will be
detected irrespective of methylation status. Additionally,
the array only measured a speciﬁc subset of CpG islands.
Methylation of additional adjacent CpGs may be needed to
down regulate expression of some genes.
Increased methylation of genes in the JNK signaling
pathway, including MAPK10 and MAP3K1, were seen in
supratentorial and spinal tumors. This pathway can induce
apoptosis under stress conditions such as exposure to
inﬂammatory cytokines or environmental factors including
chemotherapeutic drugs [14]. MAPK10 gene expression
inversely correlated with methylation levels. This gene has
been found to be methylated in a number of cancers
including glioma [35, 72]. MAPK10 expression has also
been shown to be lost in brain tumor cell lines [73]. In the
human body MAPK10 expression is restricted to speciﬁc
organs including the brain [33, 42]. Functional studies have
shown that in a MAPK10 knockout mouse, hippocampal
neurons are resistant to glutamate induced excitotoxicity
suggesting a role for signaling through MAPK10 in neu-
ronal cell death [32, 71].
Fig. 5 Methylation levels measured by bisulphite sequencing and the
methylation array displayed a signiﬁcant correlation for the selected
genes. a MAPK10 (Pearson’s r = 0.75, p = 0.0004), b PPARG
(Pearson’s r = 0.89, p = 3 9 10
-6), c FABP3 (Pearson’s r = 0.56,
p = 0.026), d EYA4 (Pearson’s r = 0.57, p = 0.053), e CRIP1
(Pearson’s r = 0.94, p = 1.4 9 10
-6), f IRF7 (Pearson’s r = 0.93,
p = 1.4 9 10
-5). Tumors are labeled on the x-axis; PF posterior
fossa, ST supratentorial, SP spinal. For the bisulphite sequencing data
the level of methylation is represented by the percentage of cytosine.
For the array data the methylation level is represented by the beta
value
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123At the expression level we found the majority of genes
involved in the JNK pathway to be up-regulated in supra-
tentorial tumors. However, these genes were all upstream
of MAPK10. The downstream target of MAPK10, JUN,
displayed decreased expression in supratentorial tumors, as
seen for MAPK10 itself. This may suggest that the pathway
is being activated in supratentorial tumors to induce cell
death. However, inactivation of MAPK10 by DNA meth-
ylation inhibits this process.
PPARG was hypermethylated in supratentorial and
spinal tumors relative to posterior fossa tumors. An inverse
correlation was seen at the mRNA expression level in our
analysis and in a previous study [62]. PPARG is a tran-
scription factor that plays a role in many physiological
processes including cell growth. The gene has been
implicated in many cancers including colon cancer where
reduced expression through hypermethylation was associ-
ated with progression and an adverse outcome [53].
Treatment of glioma cells in vitro and in vivo with PPARG
agonists decreased cell growth and induced apoptosis
[3, 11, 21]. If a similar effect is seen in ependymoma this
may be a potential therapeutic target.
We found the tumor suppressor gene RASSF1A to be
hypermethylated in intracranial ependymomas. This gene
has been shown to be methylated in a large number of
cancers including a high percentage of ependymomas
[1, 22, 46]. RASSF1A has a large number of functions
including a role in regulating cell cycle progression and
induction of apoptosis [57]. Other genes involved in
apoptosis, identiﬁed in our analysis, included TP73 and
HDAC1. TP73, which was hypermethylated in supraten-
torial tumors, has also been shown to be methylated in
ependymoma previously [2, 22]. It has been shown to
induce apoptosis in conjunction with RASSF1A [43].
HDAC1 was found to be hypermethylated in spinal
tumors.
Fig. 6 Hierarchical clustering of all ependymomas and the fetal
neural stem cell line ReNcell VM, using only probes that displayed a
signiﬁcant difference in methylation between ependymomas from
different locations (a). Clustering was carried out using the ‘pvclust’
package in R. AU p values are displayed in red. The neural stem cells
segregated with supratentorial and spinal tumors. These groupings
were conﬁrmed using principal component analysis (b)
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123EYA4 was hypermethylated in posterior fossa and
supratentorial tumors. The gene encodes a member of the
eyes absent protein family of transcription factors and
plays a role in the development of the eye and inner ear in
humans [7, 70]. It has previously been shown to be
hypermethylated in other cancers, including colorectal
cancer and Barrett’s esophagus, suggesting a tumor sup-
pressor role [50, 76]. We found an inverse correlation at the
mRNA expression level which has also been found previ-
ously [62].
A relatively low number of genes were hypermethylated
in posterior fossa ependymomas. FABP3 is a member of
the intracellular lipid binding protein family. It binds fatty
acids, plus other hydrophobic compounds, and regulates
their physiological functions [37]. It may play a role in
brain development as it is expressed in neurons [51]. IRF7
is a member of the interferon regulatory transcription factor
family and plays a role in the transcriptional activation of
virus inducible genes. It may also play a role in responding
to cellular stresses such as DNA damage [31]. CRIP1 has
been identiﬁed as a novel biomarker in cancers such as
breast and cervical [9, 39]. It has also been shown to be
hypomethylated in prostate cancer [65].
We identiﬁed a number of pathways involved in both the
innate and adaptive immune system, particularly cytokine
signaling, which displayed differential regulation between
tumor groups. Many studies have demonstrated that a host
immune response prevented tumor growth [17]. In epen-
dymoma up-regulation of genes involved in the innate and
adaptive immune response has been linked to a better
outcome [16]. Although we did not ﬁnd a link to outcome
in our data analysis, methylation of genes involved in
immunity may be one mechanism that suppresses the
immune response in ependymoma. Methylation of genes
involved in the immune system has also been seen in other
cancers including melanoma [12]. Additionally, immune
suppression has been shown to occur in different cancers
including glioblastoma where it has been linked to tumor
progression [59, 66].
A number of genes have been found to be methylated in
ependymoma in previous studies. As discussed above we
identiﬁed hypermethylation of RASSF1A and TP73 which
have both been identiﬁed in previous research [2, 22, 46].
Our results also identiﬁed methylation of HIC1 and CASP8
agreeing with previous studies [22, 46, 64]. We found no
evidence of methylation of CDKN2A, CDKN2B or
MGMT which have all previously displayed hypermethy-
lation in a proportion of ependymomas studied [22, 46, 58].
A study by Christensen et al. [10] analyzed the meth-
ylation status of 15 adult ependymomas. Comparison with
adult temporal lobe identiﬁed hyper and hypomethylated
genes. A small number of these genes were identiﬁed in our
analysis, the majority of which were hypomethylated in
adult ependymomas and the posterior fossa tumors in our
cohort. This included CHI3L2, TJP2, RBP1 and NAT2,
which displayed an inverse correlation with mRNA
expression in our study. Additionally RASSF1 was found
to be hypermethylated as we found in all intracranial
pediatric ependymomas. If adult and pediatric ependymo-
mas have similar methylation proﬁles the results would
suggest the tumors in the study by Christensen et al. were
from the posterior fossa region. However, no location
information was given. Genomically, pediatric and adult
ependymomas have been shown to be different [30].
Additionally, normal fetal and adult brains show differ-
ences in methylation patterns [36, 74]. This would suggest
pediatric and adult ependymoma may differ at the meth-
ylation level as well.
In conclusion, we have generated a global view of the
methylation proﬁle of ependymoma. Our data suggest that
epigenetic silencing of tumor suppressor genes is an
important mechanism in ependymoma pathogenesis in
supratentorial and spinal tumors. Our integrated analysis
has allowed us to identify candidate pathways and genes
with potential methylation induced expression changes
which may play a role in tumor pathogenesis.
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